Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinzaparin pharmacokinetics and efficacy during SLEDD in ICU patients
2018-001774-23Phase 4Terminated
- Sponsor
- Tampere University Hospital
- Start
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tinzaparin in venous thromboembolism (VTE) (2 arms), sponsored by Tampere University Hospital. Primary endpoint: Plasma anti-FXa concentration at 4 hours from onset of SLEDD. Started Jul 2018; status: terminated.
02
Drugs
tinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2018-001774-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001774-23.